Breast Density - It's the Iowa Law
Once you're logged in, click the "ENTER" button found in the Course Summary box to the right. Your registration will then be confirmed.
Once you register for the course, you will have 180 days (approximately 6 months) from the date of enrollment to complete the course. The exact date that your access expires will be indicated within the Course Summary box on this webpage.
Beginning January 1, 2018 with the enactment of Iowa law (SF250), all Iowa facilities that provide mammography service are required by law to notify patients of their breast density. This new regulation was mandated by the Iowa Department of Public Health.
Breast density is determined through a woman’s mammogram and described as one of four categories. 40% of women age 40 and over have dense breasts. Cancer is 4-6 times more likely in women with extremely dense breasts than in women with fatty breasts. Though mammograms find some cancers not seen on other screening tests, in dense breasts, mammograms will miss more than 50% of the cancers present. Other screening tests, such as ultrasound or breast MRI, in addition to mammography substantially increase detection of early stage breast cancers in dense breasts.
For more information, visit densebreast-info.org/.
Effective no later than March 1, 2018, Iowa Administrative Code will require radiologists to include density information in every written report of mammographic findings sent directly to the patient. At the completion of this course the attendee should:
- Describe the significance of increased breast density, including its effect on the risk of developing breast cancer and its effect on early diagnosis by mammography.
- List four categories of breast density.
- Describe the consequences of each to the patient.
- Advise patients on maneuvers that will enhance early diagnosis and/or reduce risk of developing breast cancer.
Date of original release: February 1, 2018
Most recent review/update: February 1, 2018
Termination date: January 31, 2021
Robert R. Shreck, MD
Dr. Shreck completed his undergraduate work at the University of Iowa where he majored in Pre-Medical studies in 1971. He graduated from the University of Iowa Medicine in 1974. Dr. Shreck completed a residency at the University of Utah School Of Medicine, in 1977. He also completed a fellowship in Medical Oncology and Hematology at University of Utah School of Medicine in Salt Lake City, Utah in 1979. Dr. Shreck is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology.
Dr. Shreck and his wife returned to his home town of Des Moines, Iowa in 1979 to begin practicing Medical Oncology and Hematology at Iowa Methodist Medical Center. He was Medical Director of the Blood Center of Central Iowa from 1979 to 1983. Dr. Shreck enjoys his farm home in Decatur County, Iowa and the lakes of Minnesota. Dr. Shreck and his wife have two sons and one daughter. He is also an avid ultra-light aircraft aficionado.
Relevant to the content of this CME activity, Dr. Shreck indicated he has no financial relationships to disclose.
Continuing Education Credit
- DO: Des Moines University is accredited by the American Osteopathic Association (AOA) and approves this enduring materials activity for 0.5 AOA Category 2-B credit(s).
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and Cancer Center of Iowa. Des Moines University (DMU) is accredited by the IMS to provide continuing medical education for physicians. DMU designates this enduring materials activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Other Health Professionals: This enduring materials activity is designated for 0.5 AMA PRA Category 1 Credit(s)™.
No commercial interest company provided financial support for this continuing education activity.
Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. They will also disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
- 0.50 AMA PRA Category 1 Credits™
- 0.50 AOA Category 2B
- 0.50 CE Contact Hour(s)